Traders Purchase High Volume of ALT5 Sigma Call Options (NASDAQ:ALTS)

ALT5 Sigma Corporation (NASDAQ:ALTS) was the recipient of some unusual options trading activity on Monday. Stock traders bought 5,152 call options on the stock. This is an increase of approximately 198% compared to the typical daily volume of 1,727 call options.

Institutional Trading of ALT5 Sigma

Hedge funds and other institutional investors have recently modified their holdings of the business. Bridgeway Capital Management LLC boosted its position in ALT5 Sigma by 9.4% during the 2nd quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock worth $140,000 after acquiring an additional 1,661 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of ALT5 Sigma by 23.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 45,322 shares of the company’s stock valued at $50,000 after buying an additional 8,742 shares during the period. Profund Advisors LLC acquired a new stake in shares of ALT5 Sigma during the 3rd quarter valued at $28,000. Arete Wealth Advisors LLC purchased a new position in shares of ALT5 Sigma during the 3rd quarter valued at $28,000. Finally, Geode Capital Management LLC increased its stake in shares of ALT5 Sigma by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 1,331,963 shares of the company’s stock worth $1,466,000 after acquiring an additional 12,400 shares during the last quarter. Institutional investors and hedge funds own 6.27% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ALT5 Sigma in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, ALT5 Sigma has an average rating of “Sell”.

ALT5 Sigma Stock Performance

Shares of ALTS traded down $0.11 during mid-day trading on Monday, hitting $1.13. The company’s stock had a trading volume of 3,798,200 shares, compared to its average volume of 3,608,167. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.79 and a current ratio of 0.79. The firm has a 50-day moving average price of $1.63 and a 200 day moving average price of $1.96. ALT5 Sigma has a fifty-two week low of $1.00 and a fifty-two week high of $10.95.

ALT5 Sigma (NASDAQ:ALTS) last issued its earnings results on Monday, January 12th. The company reported $0.29 earnings per share for the quarter. The firm had revenue of $7.58 million during the quarter. ALT5 Sigma had a net margin of 133.06% and a return on equity of 8.60%.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.